Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyCapital Bluecross CGM Prior Auth Coverage Update |…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy N/A

    Continuous Glucose Monitor (CGM) prior authorization

    Customize your policy alerts

    Sign up for all Capital Bluecross policy alerts

    Know when Capital Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements for Continuous Glucose Monitors (CGMs) for Capital Blue Cross beneficiaries, including clinical criteria, preferred devices, and approval duration. Applies to providers requesting coverage for CGM systems for members covered by Capital Blue Cross.

    Policy Summary
    PayerCapital Bluecross
    PolicyContinuous Glucose Monitor (CGM) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Last ReviewFeb 2, 2025
    Next Review DateFeb 1, 2025
    Key ActionObtain prior authorization for non-preferred CGMs after trial of one preferred CGM and provide documentation of qualifying hypoglycemic events or recent prescriber visit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsLength of approval
    5+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preferred systems
    DiabetesDiagnosis required
    LCD referencedMedicare alignment

    Coverage Criteria for Continuous Glucose Monitors (CGMs)

    Initial Approval

    Covered when ALL of the following are met:

    Root

    • 1. Diabetes diagnosis: The beneficiary has diabetes mellitus
    • 2. Treatment / Hypoglycemia criteria

      • 2.A Insulin treated: Beneficiary is insulin treated
      • 2.B Non-insulin treated with hypoglycemia

        • 2.B.i Recurrent level 2 events: History of recurrent (more than one) level 2 hypoglycemic events AND documentation of BOTH: (a) at least ONE of: glucose values for qualifying event(s) < 54 mg/dL OR classification of the episode(s) as level 2 OR BGM logs reflecting the specific qualifying events (< 54 mg/dL); AND (b) documentation of more than one prior medication adjustment and/or modification to the treatment plan prior to the most recent level 2 event< 54 mg/dL (3.0 mmol/L)
        • 2.B.ii Level 3 event: History of at least one level 3 hypoglycemic event characterized by altered mental and/or physical state AND documentation of BOTH: (a) at least ONE of: glucose values for the qualifying event(s) < 54 mg/dL OR classification as level 3 OR BGM log reflecting the specific qualifying event (< 54 mg/dL); AND (b) indication that third-party assistance was required for treatment of hypoglycemia< 54 mg/dL (3.0 mmol/L)
    • 3. Prescriber visit: Either the prescriber documents an in-person or telehealth visit within 6 months prior to ordering confirming criteria 1–2 are met, OR if previously approved, the prescriber documents a visit confirming continued adherence and use of the CGM
    • 4. Preferred device requirement: Either the requested CGM is a preferred CGM OR the prescriber has indicated the beneficiary failed or has limitations of use of a preferred CGM (trial of one preferred CGM required before non-preferred)

    Non-preferred Continuous Glucose Monitor (CGM) products require prior authorization. Approval for a non-preferred CGM will only be granted after the beneficiary has trialed ONE preferred CGM system (examples: Dexcom or FreeStyle) unless the prescriber documents failure or limitations of the preferred device. When prior authorization is required, approval is contingent on meeting all clinical criteria in the evaluation section and, when approved, coverage is authorized for 12 months.

    The preferred agents listed for the CGM program include Dexcom G6, Dexcom G7, FreeStyle Libre, FreeStyle Libre 2, and FreeStyle Libre 3. Prior authorization (PA) applies only to non-preferred products; prescribers requesting a non-preferred CGM must indicate that a preferred product was tried and either failed or had limitations that justify the non-preferred request.

    Requests for CGM coverage that do not document a diagnosis of diabetes mellitus are not supported. Similarly, requests are not supported when the beneficiary does not meet the required treatment or hypoglycemia criteria — specifically, either being insulin treated or meeting the documented hypoglycemia thresholds and history described in the criteria (recurrent level 2 events or at least one level 3 event with required documentation).

    Ensure submitted requests include the required clinical documentation (diagnosis and evidence of qualifying treatment or hypoglycemic events) because absence of these items is a primary reason for denial.

    Coding and Identifiers

    Target device GPIs / Multisource codesmixed
    97202012026200Dexcom G6 receiver / Dexcom G7 receiver / FreeStyle Libre reader / FreeStyle Libre 2 Reader / FreeStyle Libre 3 Reader / Guardian Real-Time replacement monitor / Guardian Real-Time, Real-Time Pediatric replacement monitor
    97202012066300Dexcom G6 transmitter / Guardian Link 3 transmitter / Guardian 4 transmitter kit / Minilink Real Time transmitter / Minimed 630G Guardian Press Starter transmitter kit / Paradigm Real-Time transmitter
    97202012046300Dexcom G6 sensor / Dexcom G7 sensor / FreeStyle Libre sensor / FreeStyle Libre 2 Sensor / FreeStyle Libre 2 Plus Sensor / FreeStyle Libre 3 Sensor / FreeStyle Libre 3 Plus Sensor / Enlite Glucose sensor / Guardian Sensor 3 / Guardian 4 sensor / Simplera Sync Sensor
    Hypoglycemia glucose threshold — numeric threshold used for qualifying events
    Numeric thresholdGlucose < 54 mg/dL (3.0 mmol/L)
    Usage in criteriaAcceptable documentation for qualifying events: measured glucose value less than 54 mg/dL
    Alternate documentationBGM testing log documenting specific events with glucose < 54 mg/dL may be incorporated into the medical record

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization required for non-preferred CGMs

    Prior authorization is required for non-preferred continuous glucose monitor (CGM) products. Approval is granted only when all listed clinical criteria are met; length of approval is 12 months.

    Step Therapy

    Preferred CGM trial required before non-preferred

    The beneficiary must trial ONE preferred CGM system (Dexcom OR FreeStyle) before a non-preferred CGM will be approved. If the prescriber requests a non-preferred device without that trial, the prescriber must indicate failure or limitations of the preferred CGM.

    Documentation Required

    Definitions

    rtCGM vs iCGM — near real-time vs intermittently scanned CGM distinctions
    rtCGM (real-time CGM)Provides near real-time interstitial glucose data and can warn users if glucose is trending toward hypoglycemia or hyperglycemia (alerts).
    iCGM (intermittently viewed CGM)Records continuous glucose measurements but requires the user to scan the sensor to view data; does not provide real-time alerts for impending hypo/hyperglycemia.
    Common capabilityBoth technologies track time in range and glucose trends, supporting diabetes management beyond HbA1c and SMBG alone.
    Level 2 hypoglycemia — numeric definition used as qualifying event
    Numeric definitionLevel 2 hypoglycemia is defined as glucose less than 54 mg/dL (3.0 mmol/L).
    Role in criteria

    Background

    Continuous Glucose Monitors (CGMs) measure interstitial glucose continuously and provide information that complements HbA1c and self-monitoring of blood glucose. CGMs enable assessment of time in range, detection of glucose variability, and identification of hypoglycemia trends that single-point measurements may miss. Real-time CGM (rtCGM) systems can provide near real-time glucose data and alerts for impending hypo- or hyperglycemia, while intermittently viewed CGM (iCGM) systems require the user to scan the sensor to view glucose data.

    Clinical justification for CGM use includes situations where beneficiaries have diabetes mellitus and either require insulin therapy or have a documented history of clinically significant hypoglycemia. The policy uses level 2 hypoglycemia (glucose <54 mg/dL [3.0 mmol/L]) and level 3 hypoglycemia (events requiring third-party assistance) as qualifying event thresholds that support CGM coverage when properly documented.

    Policy Summary
    PayerCapital Bluecross
    PolicyContinuous Glucose Monitor (CGM) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Last ReviewFeb 2, 2025
    Next Review DateFeb 1, 2025
    Key ActionObtain prior authorization for non-preferred CGMs after trial of one preferred CGM and provide documentation of qualifying hypoglycemic events or recent prescriber visit.
    SourceLink
    On This Page
    Coverage Criteria for Continuous Glucose Monitors (CGMs)Coding and IdentifiersProvider Actions, Prior Authorization & DocumentationDefinitionsBackground

    Document qualifying hypoglycemic events

    Include documentation of qualifying hypoglycemic events: glucose values less than 54 mg/dL (3.0 mmol/L), classification of events as level 2 or level 3, or incorporation of the beneficiary's BGM testing log showing the specific qualifying events.

    Denial Risk

    Denial triggers for insufficient documentation or unmet criteria

    Requests may be denied if the beneficiary does not have documentation of diabetes or does not meet the required clinical criteria (e.g., not insulin-treated or lacking qualifying hypoglycemia documentation), or if required prescriber visit documentation within six months is not provided.

    • No diabetes mellitus diagnosis documented
    • Does not meet treatment/hypoglycemia criteria (insulin-treated OR qualifying level 2/3 events documented)
    • No in-person or telehealth visit documented within 6 months prior to ordering
    Used as a qualifying event for non–insulin-treated beneficiaries when there is a history of recurrent (more than one) level 2 events with documentation.
    Acceptable evidenceDocumentation can include measured glucose values <54 mg/dL, classification as level 2, or BGM testing logs showing the events.
    Level 3 hypoglycemia — qualitative definition requiring third-party assistance
    Qualitative definitionLevel 3 hypoglycemia is characterized by an altered mental and/or physical state requiring third‑party assistance for treatment.
    Documentation requiredMust include at least one of: glucose values <54 mg/dL, classification as level 3, or BGM log documenting the event, plus indication that third‑party assistance was required.
    Use in approvalA history of at least one level 3 event with the required documentation meets the hypoglycemia criterion for CGM coverage when combined with other criteria.